Revelation Biosciences, Inc. (REVB)
NASDAQ: REVB · Real-Time Price · USD
0.866
-0.019 (-2.16%)
At close: Sep 18, 2024, 4:00 PM
0.860
-0.006 (-0.69%)
After-hours: Sep 18, 2024, 7:20 PM EDT

Revelation Biosciences Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21 Dec '20
Selling, General & Admin
4.74.515.495.041.23
Research & Development
4.824.155.386.912.56
Operating Expenses
9.538.6610.8611.953.8
Operating Income
-9.53-8.66-10.86-11.95-3.8
Other Non Operating Income (Expenses)
-6.378.540.03-0.040
Pretax Income
-15.9-0.12-10.83-11.99-3.8
Net Income
-15.9-0.12-10.83-11.99-3.8
Net Income to Common
-15.9-0.12-10.83-11.99-3.8
Shares Outstanding (Basic)
100--
Shares Outstanding (Diluted)
100--
Shares Change (YoY)
396.18%215.00%---
EPS (Basic)
-19.54-0.53-149.20--
EPS (Diluted)
-19.55-0.53-149.20--
Free Cash Flow
-9.06-7.29-11.22-11.22-2.13
Free Cash Flow Per Share
-11.13-31.87-154.57--
EBITDA
-9.5-8.63-10.84-11.93-
D&A For EBITDA
0.030.030.030.02-
EBIT
-9.53-8.66-10.86-11.95-3.8
Source: S&P Capital IQ. Standard template. Financial Sources.